<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Obes Metab</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Obes Metab</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1463-1326</journal-id><journal-id journal-id-type="publisher-id">DOM</journal-id><journal-title-group><journal-title>Diabetes, Obesity &#x00026; Metabolism</journal-title></journal-title-group><issn pub-type="ppub">1462-8902</issn><issn pub-type="epub">1463-1326</issn><publisher><publisher-name>Blackwell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27800649</article-id><article-id pub-id-type="pmc">5347937</article-id><article-id pub-id-type="doi">10.1111/dom.12817</article-id><article-id pub-id-type="publisher-id">DOM12817</article-id><article-categories><subj-group subj-group-type="overline"><subject>Brief Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Brief Reports</subject></subj-group></article-categories><title-group><article-title>Effects of <styled-content style="fixed-case">DPP</styled-content>&#x02010;4 inhibitor linagliptin and <styled-content style="fixed-case">GLP</styled-content>&#x02010;1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open&#x02010;label, 2&#x02010;arm parallel comparative, exploratory trial</article-title><alt-title alt-title-type="left-running-head">YABE et al.</alt-title></title-group><contrib-group><contrib id="dom12817-cr-0001" contrib-type="author" corresp="yes"><name><surname>Yabe</surname><given-names>Daisuke</given-names></name><degrees>M.D., Ph.D.</degrees><address><email>ydaisuke-kyoto@umin.ac.jp</email></address><xref ref-type="aff" rid="dom12817-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="dom12817-aff-0002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="dom12817-aff-0003">
<sup>3</sup>
</xref><xref ref-type="aff" rid="dom12817-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="dom12817-cr-0002" contrib-type="author"><name><surname>Eto</surname><given-names>Takashi</given-names></name><degrees>M.D., Ph.D.</degrees><xref ref-type="aff" rid="dom12817-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="dom12817-cr-0003" contrib-type="author"><name><surname>Shiramoto</surname><given-names>Masanari</given-names></name><degrees>M.D., Ph.D.</degrees><xref ref-type="aff" rid="dom12817-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="dom12817-cr-0004" contrib-type="author"><name><surname>Irie</surname><given-names>Shin</given-names></name><degrees>M.D.</degrees><xref ref-type="aff" rid="dom12817-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="dom12817-cr-0005" contrib-type="author"><name><surname>Murotani</surname><given-names>Kenta</given-names></name><degrees>Ph.D.</degrees><xref ref-type="aff" rid="dom12817-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="dom12817-cr-0006" contrib-type="author"><name><surname>Seino</surname><given-names>Yusuke</given-names></name><degrees>M.D., Ph.D.</degrees><xref ref-type="aff" rid="dom12817-aff-0007">
<sup>7</sup>
</xref></contrib><contrib id="dom12817-cr-0007" contrib-type="author"><name><surname>Kuwata</surname><given-names>Hitoshi</given-names></name><degrees>M.D.</degrees><xref ref-type="aff" rid="dom12817-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="dom12817-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="dom12817-cr-0008" contrib-type="author"><name><surname>Kurose</surname><given-names>Takeshi</given-names></name><degrees>M.D., Ph.D.</degrees><xref ref-type="aff" rid="dom12817-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="dom12817-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="dom12817-cr-0009" contrib-type="author"><name><surname>Seino</surname><given-names>Susumu</given-names></name><degrees>M.D., D.M.Sci.</degrees><xref ref-type="aff" rid="dom12817-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="dom12817-cr-0010" contrib-type="author"><name><surname>Ahr&#x000e9;n</surname><given-names>Bo</given-names></name><degrees>M.D., Ph.D.</degrees><xref ref-type="aff" rid="dom12817-aff-0008">
<sup>8</sup>
</xref></contrib><contrib id="dom12817-cr-0011" contrib-type="author" corresp="yes"><name><surname>Seino</surname><given-names>Yutaka</given-names></name><degrees>M.D., Ph.D.</degrees><address><email>seino.yutaka@e2.kepco.co.jp</email></address><xref ref-type="aff" rid="dom12817-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="dom12817-aff-0002">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="dom12817-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Yutaka Seino Distinguished Center for Diabetes Research</named-content><institution>Kansai Electric Power Medical Research Institute</institution><named-content content-type="city">Kobe</named-content><country country="JP">Japan</country></aff><aff id="dom12817-aff-0002"><label><sup>2</sup></label><named-content content-type="organisation-division">Center for Diabetes, Endocrinology and Metabolism</named-content><institution>Kansai Electric Power Hospital</institution><named-content content-type="city">Osaka</named-content><country country="JP">Japan</country></aff><aff id="dom12817-aff-0003"><label><sup>3</sup></label><named-content content-type="organisation-division">Center for Metabolism and Clinical Nutrition</named-content><institution>Kansai Electric Power Hospital</institution><named-content content-type="city">Osaka</named-content><country country="JP">Japan</country></aff><aff id="dom12817-aff-0004"><label><sup>4</sup></label><named-content content-type="organisation-division">Division of Molecular and Metabolic Medicine</named-content><institution>Kobe University Graduate School of Medicine</institution><named-content content-type="city">Kobe</named-content><country country="JP">Japan</country></aff><aff id="dom12817-aff-0005"><label><sup>5</sup></label><named-content content-type="organisation-division">Hakata Clinic</named-content><institution>SOUSEIKAI</institution><named-content content-type="city">Fukuoka</named-content><country country="JP">Japan</country></aff><aff id="dom12817-aff-0006"><label><sup>6</sup></label><named-content content-type="organisation-division">Division of Biostatistics, Clinical Research Center</named-content><institution>Aichi Medical University Hospital</institution><named-content content-type="city">Nagakute</named-content><country country="JP">Japan</country></aff><aff id="dom12817-aff-0007"><label><sup>7</sup></label><named-content content-type="organisation-division">Departments of Endocrinology and Diabetes Metabolic Medicine</named-content><institution>Nagoya University Graduate School of Medicine</institution><named-content content-type="city">Nagoya</named-content><country country="JP">Japan</country></aff><aff id="dom12817-aff-0008"><label><sup>8</sup></label><named-content content-type="organisation-division">Department of Clinical Sciences</named-content><institution>Lund University</institution><named-content content-type="city">Lund</named-content><country country="SE">Sweden</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Corresponding Authors</bold>: Daisuke Yabe and Yutaka Seino, Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, 1&#x02010;5&#x02010;6 Minatojimaminamimachi, Chuo&#x02010;ku, Kobe 650&#x02010;0047, Japan (<email>ydaisuke-kyoto@umin.ac.jp</email>; <email>seino.yutaka@e2.kepco.co.jp</email>).</corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>11</month><year>2016</year></pub-date><pub-date pub-type="ppub"><month>3</month><year>2017</year></pub-date><volume>19</volume><issue>3</issue><issue-id pub-id-type="doi">10.1111/dom.2017.19.issue-3</issue-id><fpage>442</fpage><lpage>447</lpage><history><date date-type="received"><day>21</day><month>9</month><year>2016</year></date><date date-type="rev-recd"><day>25</day><month>10</month><year>2016</year></date><date date-type="accepted"><day>26</day><month>10</month><year>2016</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2017 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2016 The Authors. Diabetes, Obesity and Metabolism published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution&#x02010;NonCommercial&#x02010;NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:DOM-19-442.pdf"/><abstract id="dom12817-abs-0001"><p id="dom12817-para-0001">Dipeptidyl peptidase&#x02010;4 (<styled-content style="fixed-case">DPP</styled-content>&#x02010;4) inhibitors reduce the risk of hypoglycaemia, possibly through augmentation of glucose&#x02010;dependent insulinotropic polypeptide (<styled-content style="fixed-case">GIP</styled-content>) action, but not that of glucagon&#x02010;like peptide&#x02010;1 (<styled-content style="fixed-case">GLP</styled-content>&#x02010;1) on glucagon secretion. To examine this model in Japanese individuals with type 2 diabetes (<styled-content style="fixed-case">T2D</styled-content>), the effects of the <styled-content style="fixed-case">DPP</styled-content>&#x02010;4 inhibitor linagliptin on glucagon and other counter&#x02010;regulatory hormone responses to hypoglycaemia were evaluated and compared with those of the <styled-content style="fixed-case">GLP</styled-content>&#x02010;1 receptor agonist liraglutide in a multi&#x02010;centre, randomized, open&#x02010;label, 2&#x02010;arm parallel comparative, exploratory trial. Three&#x02010;step hypoglycaemic clamp glucose tests preceded by meal tolerance tests were performed before and after 2&#x02010;week treatment with the drugs. Glucagon levels were increased during the hypoglycaemic clamp test at 2.5 mmol/L. This increase was similar in the linagliptin and liraglutide groups, both before and after the 2&#x02010;week treatment. Changes in other counter&#x02010;regulatory hormones (ie, growth hormone, cortisol, epinephrine and norepinephrine) were also similar between the groups, but were suppressed substantially after 2&#x02010;week treatment compared to baseline. In conclusion, we confirmed that the glucagon response to hypoglycaemia was not affected by linagliptin or liraglutide treatment in Japanese individuals with <styled-content style="fixed-case">T2D</styled-content>.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="dom12817-kwd-0001"><styled-content style="fixed-case">DPP</styled-content>&#x02010;4 inhibitor</kwd><kwd id="dom12817-kwd-0002"><styled-content style="fixed-case">GLP</styled-content>&#x02010;1 receptor agonist</kwd><kwd id="dom12817-kwd-0003">glucagon response</kwd><kwd id="dom12817-kwd-0004">hypoglycaemia</kwd><kwd id="dom12817-kwd-0005">sympatho&#x02010;adrenal response</kwd></kwd-group><funding-group><award-group><funding-source>Nippon Boehringer Ingelheim</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Eli Lilly and Company</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Kyoto University</funding-source></award-group></funding-group><funding-group><award-group><funding-source>GlaxoSmithKline</funding-source></award-group></funding-group><counts><fig-count count="0"/><table-count count="2"/><page-count count="6"/><word-count count="4319"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>dom12817</meta-value></custom-meta><custom-meta><meta-name>header-id</meta-name><meta-value>dom12817-hdr-0001</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>March 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.0.8 mode:remove_FC converted:13.03.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="dom12817-cit-0000">
<string-name>
<surname>Yabe</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Eto</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Shiramoto</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Irie</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Murotani</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Seino</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Kuwata</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kurose</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Seino</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ahren</surname>
<given-names>B</given-names>
</string-name> and <string-name>
<surname>Seino</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Effects of DPP&#x02010;4 inhibitor linagliptin and GLP&#x02010;1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open&#x02010;label, 2&#x02010;arm parallel comparative, exploratory trial</article-title>, <source>Diabetes Obes Metab</source>, <year>2017</year>;<volume>19</volume>(<issue>3</issue>):<fpage>442</fpage>&#x02013;<lpage>447</lpage>.<pub-id pub-id-type="pmid">27800649</pub-id></mixed-citation>
</p></notes><notes><fn-group id="dom12817-ntgp-0001a"><fn id="dom12817-note-0001a"><p>
<bold>Funding information</bold> This study was financially supported by Nippon Boehringer Ingelheim and Eli Lilly and Company.</p></fn></fn-group></notes></front><body><sec id="dom12817-sec-0001"><label>1</label><title>INTRODUCTION</title><p id="dom12817-para-0002">Dipeptidyl peptidase&#x02010;4 (DPP&#x02010;4) inhibitors are widely used in treatment of type 2 diabetes (T2D).<xref rid="dom12817-bib-0001" ref-type="ref">1</xref>, <xref rid="dom12817-bib-0002" ref-type="ref">2</xref> DPP&#x02010;4 inhibitors increase biologically intact forms of glucose&#x02010;dependent insulinotropic polypeptide (GIP) and glucagon&#x02010;like peptide&#x02010;1 (GLP&#x02010;1), both of which enhance glucose&#x02010;induced insulin secretion from pancreatic &#x003b2;&#x02010;cells.<xref rid="dom12817-bib-0003" ref-type="ref">3</xref>, <xref rid="dom12817-bib-0004" ref-type="ref">4</xref> GLP&#x02010;1 suppresses glucagon secretion from pancreatic &#x003b1;&#x02010;cells when glucose levels are high,<xref rid="dom12817-bib-0005" ref-type="ref">
<sup>5</sup>
</xref>, <xref rid="dom12817-bib-0006" ref-type="ref">
<sup>6</sup>
</xref> whereas GIP augments glucagon secretion in response to hypoglycaemia.<xref rid="dom12817-bib-0007" ref-type="ref">7</xref>, <xref rid="dom12817-bib-0008" ref-type="ref">8</xref>, <xref rid="dom12817-bib-0009" ref-type="ref">9</xref>, <xref rid="dom12817-bib-0010" ref-type="ref">10</xref> Thus, enhancement of GIP and GLP&#x02010;1 actions by DPP&#x02010;4 inhibitors should contribute, not only to amelioration of hyperglycaemia, but also to mitigation of severe hypoglycaemia. It was reported that the DPP&#x02010;4 inhibitor vildagliptin enhances the glucagon response to hypoglycaemia in drug&#x02010;na&#x000ef;ve individuals with T2D,<xref rid="dom12817-bib-0011" ref-type="ref">11</xref> whereas the glucagon response to hypoglycaemia was not affected by GLP&#x02010;1 receptor (GLP&#x02010;1R) agonists.<xref rid="dom12817-bib-0012" ref-type="ref">12</xref>, <xref rid="dom12817-bib-0013" ref-type="ref">13</xref> This might suggest differing effects of DPP&#x02010;4 inhibitors and GLP&#x02010;1R agonists on the glucagon response to hypoglycaemia, which needs to be examined in head&#x02010;to&#x02010;head studies. In this study, we compared effects of the DPP&#x02010;4 inhibitor linagliptin with those of the GLP&#x02010;1R agonist liraglutide on the responses to hypoglycaemia of glucagon and other counter&#x02010;regulatory hormones in Japanese individuals with T2D.</p></sec><sec id="dom12817-sec-0002"><label>2</label><title>METHODS</title><sec id="dom12817-sec-0003"><label>2.1</label><title>Study protocol</title><p id="dom12817-para-0003">This was a multi&#x02010;centre, randomized, prospective, open&#x02010;label, 2&#x02010;arm parallel comparative, exploratory study in Japanese individuals with T2D (UMIN&#x02010;CTR clinical trial registration number: UMIN000014417). Those eligible were randomized in a 1&#x02010;to&#x02010;1 ratio to a linagliptin or liraglutide treatment group by computer&#x02010;based dynamic allocation, taking gender, age and BMI into consideration for stratified randomization based on screening results at visit 1 (V1, week &#x02212;4). A meal tolerance test (MTT) and stepped hyperinsulinaemic glucose clamp test (SHGCT) were performed at visit 2 (V2, day 0) and visit 3 (V3, day 14); blood samples were obtained and analysed as described in File S1. Subjects received study medication for 14 days (days 1&#x02010;14), linagliptin 5 mg once daily or liraglutide 0.3 mg via subcutaneous injection once daily from day 1 to day 6 and 0.6 mg from day 7 to day 14. Liraglutide up to only 0.9 mg once daily is the dosage approved in Japan. Subjects were recruited and screened in 2 medical institutions in Osaka and Fukuoka, Japan after obtaining approval of the respective ethics committees. Randomization was performed at A2 Healthcare Corp in Tokyo, Japan. Data were collected in an inpatient ward of the medical institution in Fukuoka, Japan. Recruitment of subjects began July 5, 2014 and the last follow&#x02010;up date was April 20, 2015. Written informed consent was obtained from all subjects.</p></sec><sec id="dom12817-sec-0004"><label>2.2</label><title>Study population</title><p id="dom12817-para-0004">Eligible Japanese individuals with T2D were age 40&#x02010;70 years with a body mass index (BMI) &#x0003c; 30 kg/m<sup>2</sup>, and a treatment history of a single oral hypoglycaemic agent with HbA1c 6.0% to 8.0% (42&#x02010;64 mmol/mol) or no drug treatment with HbA1c 6.0% to 8.5% (42&#x02010;69 mmol/mol). Individuals requiring insulin therapy, or those treated with insulin, DPP&#x02010;4 inhibitors or GLP&#x02010;1 receptor agonists during the 4 weeks before informed consent, or those treated with pioglitazone during the 12 weeks before informed consent were excluded, as were those with cardiac failure or history of cerebro&#x02010;cardiovascular disease or pancreatitis. The sample size was not based on a power calculation as this was an exploratory pilot study; however, the sample size would seem to be appropriate in the context of previous, related studies.<xref rid="dom12817-bib-0009" ref-type="ref">9</xref>, <xref rid="dom12817-bib-0011" ref-type="ref">11</xref>
</p></sec><sec id="dom12817-sec-0005"><label>2.3</label><title>Study assessments</title><p id="dom12817-para-0005">Major outcomes were changes in glucagon and other counter&#x02010;regulatory hormones (ie, epinephrine, norepinephrine, cortisol and growth hormone [GH]) during SHGCT following 2&#x02010;week treatment with linagliptin or liraglutide in the per protocol set (PPS) population (ie, subjects who received 14&#x02010;day administration of study medication with successful completion of SHGCT on both V2 and V3). All adverse events (AE) were collected and AE by system organ class/preferred terms, serious adverse events (SAE) and discontinuation from AE were summarized for the full analysis set (FAS) population (ie, subjects who received at least 1 dose of study medication, with data from at least 1 point of safety available after drug administration, regardless of successful completion of SHGCT on either V2 or V3).</p></sec><sec id="dom12817-sec-0006"><label>2.4</label><title>Statistical analysis</title><p id="dom12817-para-0006">All analyses were performed using SAS version 9.4 (SAS Institute, Inc., Cary, North Carolina). Results are reported as mean &#x000b1; SE unless otherwise stated. Area&#x02010;under&#x02010;the curve (AUC) of each measurement was calculated according to the trapezoidal rule. Repeated measures were analysed with mixed&#x02010;design analysis of covariance (ANCOVA). The changes of each measurement from 225 to 255 minutes were tested using two sample <italic>t</italic> test. A 2&#x02010;sided <italic>P</italic> value &#x0003c; .05 was taken to indicate significant difference.</p></sec></sec><sec id="dom12817-sec-0007"><label>3</label><title>RESULTS</title><p id="dom12817-para-0007">Thirty&#x02010;five screened subjects were randomized to the linagliptin treatment group or the liraglutide treatment group; they received study assessments at V2 and V3 and were analysed as the FAS population (Table <xref rid="dom12817-tbl-0001" ref-type="table-wrap">1</xref> and Figure S1). Six of them did not reach the target blood glucose level in the hypoglycaemic phase at V2 and/or V3 and were excluded from the PPS population.</p><table-wrap id="dom12817-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Demographic and baseline characteristics of full analysis set and per protocol set populations</p></caption><table frame="hsides" rules="groups"><col width="1*" align="left" span="1"/><col width="1*" align="char" char="&#x000b1;" span="1"/><col width="1*" align="char" char="&#x000b1;" span="1"/><col width="1*" span="1"/><col width="1*" align="char" char="&#x000b1;" span="1"/><col width="1*" align="char" char="&#x000b1;" span="1"/><col width="1*" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th style="border-bottom:solid 1px #000000" align="left" id="dom12817-ent-0001" valign="bottom" rowspan="1" colspan="1"/><th colspan="3" id="dom12817-ent-0002" align="char" valign="bottom" rowspan="1">Full analysis set</th><th colspan="3" id="dom12817-ent-0003" align="char" valign="bottom" rowspan="1">Per protocol set</th></tr><tr style="border-bottom:solid 1px #000000"><th id="dom12817-ent-0004" align="left" valign="bottom" rowspan="1" colspan="1"/><th id="dom12817-ent-0005" align="char" valign="bottom" rowspan="1" colspan="1">Linagliptin</th><th id="dom12817-ent-0006" align="char" valign="bottom" rowspan="1" colspan="1">Liraglutide</th><th id="dom12817-ent-0007" valign="bottom" rowspan="1" colspan="1">
<italic>P</italic> value</th><th id="dom12817-ent-0008" align="char" valign="bottom" rowspan="1" colspan="1">Linagliptin</th><th id="dom12817-ent-0009" align="char" valign="bottom" rowspan="1" colspan="1">Liraglutide</th><th id="dom12817-ent-0010" valign="bottom" rowspan="1" colspan="1">
<italic>P</italic> value</th></tr></thead><tbody valign="top"><tr><td id="dom12817-ent-0011" align="left" valign="top" rowspan="1" colspan="1">n (male/female)</td><td id="dom12817-ent-0012" align="char" char="(" valign="top" rowspan="1" colspan="1">18 (13/5)</td><td id="dom12817-ent-0013" align="char" char="(" valign="top" rowspan="1" colspan="1">17 (12/5)</td><td id="dom12817-ent-0014" valign="top" rowspan="1" colspan="1"/><td id="dom12817-ent-0015" align="char" char="(" valign="top" rowspan="1" colspan="1">15 (11/4)</td><td id="dom12817-ent-0016" align="char" char="(" valign="top" rowspan="1" colspan="1">14 (10/4)</td><td id="dom12817-ent-0017" valign="top" rowspan="1" colspan="1"/></tr><tr><td id="dom12817-ent-0018" align="left" valign="top" rowspan="1" colspan="1">Age (years)</td><td id="dom12817-ent-0019" align="char" valign="top" rowspan="1" colspan="1">58.56 &#x000b1; 7.81</td><td id="dom12817-ent-0020" align="char" valign="top" rowspan="1" colspan="1">57.76 &#x000b1; 7.63</td><td align="char" char="." id="dom12817-ent-0021" valign="top" rowspan="1" colspan="1">.764</td><td id="dom12817-ent-0022" align="char" valign="top" rowspan="1" colspan="1">59.53 &#x000b1; 7.12</td><td id="dom12817-ent-0023" align="char" valign="top" rowspan="1" colspan="1">56.79 &#x000b1; 7.66</td><td align="char" char="." id="dom12817-ent-0024" valign="top" rowspan="1" colspan="1">.326</td></tr><tr><td id="dom12817-ent-0025" align="left" valign="top" rowspan="1" colspan="1">BMI (kg&#x0200a;/&#x0200a;m<sup>2</sup>)</td><td id="dom12817-ent-0026" align="char" valign="top" rowspan="1" colspan="1">23.82 &#x000b1; 2.29</td><td id="dom12817-ent-0027" align="char" valign="top" rowspan="1" colspan="1">23.98 &#x000b1; 3.15</td><td align="char" char="." id="dom12817-ent-0028" valign="top" rowspan="1" colspan="1">.871</td><td id="dom12817-ent-0029" align="char" valign="top" rowspan="1" colspan="1">23.47 &#x000b1; 1.93</td><td id="dom12817-ent-0030" align="char" valign="top" rowspan="1" colspan="1">23.88 &#x000b1; 3.49</td><td align="char" char="." id="dom12817-ent-0031" valign="top" rowspan="1" colspan="1">.702</td></tr><tr><td id="dom12817-ent-0032" align="left" valign="top" rowspan="1" colspan="1">Waist circumference (cm)</td><td id="dom12817-ent-0033" align="char" valign="top" rowspan="1" colspan="1">86.79 &#x000b1; 8.86</td><td id="dom12817-ent-0034" align="char" valign="top" rowspan="1" colspan="1">87.46 &#x000b1; 10.85</td><td align="char" char="." id="dom12817-ent-0035" valign="top" rowspan="1" colspan="1">.842</td><td id="dom12817-ent-0036" align="char" valign="top" rowspan="1" colspan="1">86.05 &#x000b1; 9.2</td><td id="dom12817-ent-0037" align="char" valign="top" rowspan="1" colspan="1">85.53 &#x000b1; 10.8</td><td align="char" char="." id="dom12817-ent-0038" valign="top" rowspan="1" colspan="1">.889</td></tr><tr><td id="dom12817-ent-0039" align="left" valign="top" rowspan="1" colspan="1">Duration (years)</td><td id="dom12817-ent-0040" align="char" valign="top" rowspan="1" colspan="1">4.00 &#x000b1; 3.66</td><td id="dom12817-ent-0041" align="char" valign="top" rowspan="1" colspan="1">3.59 &#x000b1; 5.73</td><td align="char" char="." id="dom12817-ent-0042" valign="top" rowspan="1" colspan="1">.801</td><td id="dom12817-ent-0043" align="char" valign="top" rowspan="1" colspan="1">4.67 &#x000b1; 3.66</td><td id="dom12817-ent-0044" align="char" valign="top" rowspan="1" colspan="1">3.50 &#x000b1; 6.02</td><td align="char" char="." id="dom12817-ent-0045" valign="top" rowspan="1" colspan="1">.530</td></tr><tr><td id="dom12817-ent-0046" align="left" valign="top" rowspan="1" colspan="1">FPG (mg/dL)</td><td id="dom12817-ent-0047" align="char" valign="top" rowspan="1" colspan="1">143.89 &#x000b1; 31.19</td><td id="dom12817-ent-0048" align="char" valign="top" rowspan="1" colspan="1">139.65 &#x000b1; 27.36</td><td align="char" char="." id="dom12817-ent-0049" valign="top" rowspan="1" colspan="1">.672</td><td id="dom12817-ent-0050" align="char" valign="top" rowspan="1" colspan="1">146.73 &#x000b1; 33.54</td><td id="dom12817-ent-0051" align="char" valign="top" rowspan="1" colspan="1">137.21 &#x000b1; 28.34</td><td align="char" char="." id="dom12817-ent-0052" valign="top" rowspan="1" colspan="1">.418</td></tr><tr><td id="dom12817-ent-0053" align="left" valign="top" rowspan="1" colspan="1">HbA1c (%)</td><td id="dom12817-ent-0054" align="char" valign="top" rowspan="1" colspan="1">7.38 &#x000b1; 0.71</td><td id="dom12817-ent-0055" align="char" valign="top" rowspan="1" colspan="1">7.21 &#x000b1; 0.59</td><td align="char" char="." id="dom12817-ent-0056" valign="top" rowspan="1" colspan="1">.441</td><td id="dom12817-ent-0057" align="char" valign="top" rowspan="1" colspan="1">7.37 &#x000b1; 0.75</td><td id="dom12817-ent-0058" align="char" valign="top" rowspan="1" colspan="1">7.14 &#x000b1; 0.57</td><td align="char" char="." id="dom12817-ent-0059" valign="top" rowspan="1" colspan="1">.375</td></tr><tr><td id="dom12817-ent-0060" align="left" valign="top" rowspan="1" colspan="1">OAD use (%)</td><td id="dom12817-ent-0061" align="char" valign="top" rowspan="1" colspan="1">0</td><td id="dom12817-ent-0062" align="char" valign="top" rowspan="1" colspan="1">0</td><td id="dom12817-ent-0063" valign="top" rowspan="1" colspan="1"/><td id="dom12817-ent-0064" align="char" valign="top" rowspan="1" colspan="1">0</td><td id="dom12817-ent-0065" align="char" valign="top" rowspan="1" colspan="1">0</td><td id="dom12817-ent-0066" valign="top" rowspan="1" colspan="1"/></tr><tr><td id="dom12817-ent-0067" align="left" valign="top" rowspan="1" colspan="1">Systolic BP (mm Hg)</td><td id="dom12817-ent-0068" align="char" valign="top" rowspan="1" colspan="1">130.44 &#x000b1; 10.99</td><td id="dom12817-ent-0069" align="char" valign="top" rowspan="1" colspan="1">128.24 &#x000b1; 9.26</td><td align="char" char="." id="dom12817-ent-0070" valign="top" rowspan="1" colspan="1">.526</td><td id="dom12817-ent-0071" align="char" valign="top" rowspan="1" colspan="1">131.40 &#x000b1; 11.56</td><td id="dom12817-ent-0072" align="char" valign="top" rowspan="1" colspan="1">127.93 &#x000b1; 8.91</td><td align="char" char="." id="dom12817-ent-0073" valign="top" rowspan="1" colspan="1">.376</td></tr><tr><td id="dom12817-ent-0074" align="left" valign="top" rowspan="1" colspan="1">Diastolic BP (mm Hg)</td><td id="dom12817-ent-0075" align="char" valign="top" rowspan="1" colspan="1">78.89 &#x000b1; 6.91</td><td id="dom12817-ent-0076" align="char" valign="top" rowspan="1" colspan="1">78.47 &#x000b1; 8.24</td><td align="char" char="." id="dom12817-ent-0077" valign="top" rowspan="1" colspan="1">.871</td><td id="dom12817-ent-0078" align="char" valign="top" rowspan="1" colspan="1">78.67 &#x000b1; 7.47</td><td id="dom12817-ent-0079" align="char" valign="top" rowspan="1" colspan="1">78.43 &#x000b1; 9.10</td><td align="char" char="." id="dom12817-ent-0080" valign="top" rowspan="1" colspan="1">.939</td></tr><tr><td id="dom12817-ent-0081" align="left" valign="top" rowspan="1" colspan="1">Total&#x02010;cholesterol (mg/dL)</td><td id="dom12817-ent-0082" align="char" valign="top" rowspan="1" colspan="1">217.28 &#x000b1; 38.44</td><td id="dom12817-ent-0083" align="char" valign="top" rowspan="1" colspan="1">224.76 &#x000b1; 45.15</td><td align="char" char="." id="dom12817-ent-0084" valign="top" rowspan="1" colspan="1">.600</td><td id="dom12817-ent-0085" align="char" valign="top" rowspan="1" colspan="1">219.13 &#x000b1; 36.38</td><td id="dom12817-ent-0086" align="char" valign="top" rowspan="1" colspan="1">217.29 &#x000b1; 44.89</td><td align="char" char="." id="dom12817-ent-0087" valign="top" rowspan="1" colspan="1">.904</td></tr><tr><td id="dom12817-ent-0088" align="left" valign="top" rowspan="1" colspan="1">HDL&#x02010;cholesterol (mg/dL)</td><td id="dom12817-ent-0089" align="char" valign="top" rowspan="1" colspan="1">59.17 &#x000b1; 16.19</td><td id="dom12817-ent-0090" align="char" valign="top" rowspan="1" colspan="1">61.41 &#x000b1; 15.74</td><td align="char" char="." id="dom12817-ent-0091" valign="top" rowspan="1" colspan="1">.680</td><td id="dom12817-ent-0092" align="char" valign="top" rowspan="1" colspan="1">61.53 &#x000b1; 16.08</td><td id="dom12817-ent-0093" align="char" valign="top" rowspan="1" colspan="1">63.21 &#x000b1; 16.78</td><td align="char" char="." id="dom12817-ent-0094" valign="top" rowspan="1" colspan="1">.785</td></tr><tr><td id="dom12817-ent-0095" align="left" valign="top" rowspan="1" colspan="1">Triglyceride (mg/dL)</td><td id="dom12817-ent-0096" align="char" valign="top" rowspan="1" colspan="1">157.39 &#x000b1; 96.03</td><td id="dom12817-ent-0097" align="char" valign="top" rowspan="1" colspan="1">120.65 &#x000b1; 34.94</td><td align="char" char="." id="dom12817-ent-0098" valign="top" rowspan="1" colspan="1">.143</td><td id="dom12817-ent-0099" align="char" valign="top" rowspan="1" colspan="1">148.20 &#x000b1; 99.38</td><td id="dom12817-ent-0100" align="char" valign="top" rowspan="1" colspan="1">112.79 &#x000b1; 32.47</td><td align="char" char="." id="dom12817-ent-0101" valign="top" rowspan="1" colspan="1">.208</td></tr><tr><td id="dom12817-ent-0102" align="left" valign="top" rowspan="1" colspan="1">DPP&#x02010;4 activity (nmol/mL/min)</td><td id="dom12817-ent-0103" align="char" valign="top" rowspan="1" colspan="1">8.73 &#x000b1; 1.66</td><td id="dom12817-ent-0104" align="char" valign="top" rowspan="1" colspan="1">9.02 &#x000b1; 1.95</td><td align="char" char="." id="dom12817-ent-0105" valign="top" rowspan="1" colspan="1">.639</td><td id="dom12817-ent-0106" align="char" valign="top" rowspan="1" colspan="1">8.76 &#x000b1; 1.72</td><td id="dom12817-ent-0107" align="char" valign="top" rowspan="1" colspan="1">9.19 &#x000b1; 2.09</td><td align="char" char="." id="dom12817-ent-0108" valign="top" rowspan="1" colspan="1">.542</td></tr></tbody></table><table-wrap-foot><fn id="dom12817-note-0003"><p>Each value represents mean &#x000b1; standard deviation.</p></fn><fn id="dom12817-note-0004"><p>Abbreviations: <styled-content style="fixed-case">BMI</styled-content>, body mass index; <styled-content style="fixed-case">BP</styled-content>, blood pressure; <styled-content style="fixed-case">DPP</styled-content>&#x02010;4, dipeptidyl peptidase&#x02010;4; <styled-content style="fixed-case">FPG</styled-content>, fasting plasma glucose; <styled-content style="fixed-case">HDL</styled-content>, high density lipoprotein; <styled-content style="fixed-case">OAD</styled-content>, oral anti&#x02010;diabetic drugs.</p></fn></table-wrap-foot></table-wrap><p id="dom12817-para-0008">MTT were performed to increase GIP and GLP&#x02010;1 prior to SHGCT. Glucose levels were similar between the linagliptin and liraglutide groups at V2, and were decreased similarly at V3, to a greater degree in the liraglutide group (Table S1 and Figure S2). C&#x02010;peptide and ISR were significantly higher in the liraglutide group at V2 and V3, and were similarly enhanced at V3 compared to V2 in both groups. Glucagon tended to be higher in the liraglutide group at V2 and V3, but was similarly suppressed at V3 compared to V2 in both groups. Intact GIP levels were similar in the two groups at V2, and were increased at V3 only in the linagliptin group; GIP levels were similar between the two groups at V2 and V3 (Table S1 and Figure S3). Total and intact GLP&#x02010;1 were not determined in the liraglutide group throughout the study because of the difficulty in differentiating liraglutide from endogenous GLP&#x02010;1.</p><p id="dom12817-para-0009">SHGCT were performed immediately after MTT. Glucose levels at V2 and V3 in both groups were similarly decreased during euglycaemic and hypoglycaemic phases (Figure S4). After discontinuation of insulin infusion at 255 minutes, blood glucose recovered similarly at V2 and V3 in both groups. The recovery from hypoglycaemia exhibited no significant difference between groups and glucose infusion rates (IIR) from 255 to 300 minutes were similar between groups and between visits. Glucose infusion rates were also similar between groups and between visits (Figure S7). ISR at V3 was higher than that at V2 during the hyperglycaemic and euglycaemic phases, but there was no difference in ISR during the hypoglycaemic phase between the two groups or between visits (Table <xref rid="dom12817-tbl-0002" ref-type="table-wrap">2</xref> and Figure S4). During the hyperglycaemic and euglycaemic phases, glucagon at V2 and V3 were nearly unchanged and were similar in both groups (Table <xref rid="dom12817-tbl-0002" ref-type="table-wrap">2</xref> and Figure S5). Glucagon increased rapidly during the hypoglycaemic phase and there was no difference in glucagon response between groups or between visits. Total GIP levels were similar between groups at V2 and V3. Intact GIP levels were similar between groups at V2, and were increased only in the linagliptin group at V3. GH, cortisol, epinephrine and norepinephrine were increased during the latter half of the hypoglycaemic phase at V2 and V3 (Table <xref rid="dom12817-tbl-0002" ref-type="table-wrap">2</xref> and Figure S6). The changes in GH, cortisol, epinephrine and norepinephrine at V3 were less than those at V2 in both groups. The overall results in the FAS population were fully consistent with those of the PPS population (data not shown).</p><table-wrap id="dom12817-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Response to hypoglycaemia in the per protocol population</p></caption><table frame="hsides" rules="groups"><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="3" align="left" id="dom12817-ent-0109" valign="bottom" colspan="1"/><th rowspan="3" align="left" id="dom12817-ent-0110" valign="bottom" colspan="1"/><th colspan="5" align="left" id="dom12817-ent-0111" valign="bottom" rowspan="1">Linagliptin</th><th colspan="5" align="left" id="dom12817-ent-0112" valign="bottom" rowspan="1">Liraglutide</th><th colspan="5" align="left" id="dom12817-ent-0113" valign="bottom" rowspan="1">
<italic>&#x00394;</italic>(V3&#x0200a;&#x02010;&#x0200a;V2)</th></tr><tr style="border-bottom:solid 1px #000000"><th colspan="2" align="left" id="dom12817-ent-0114" valign="bottom" rowspan="1">V2</th><th colspan="2" align="left" id="dom12817-ent-0115" valign="bottom" rowspan="1">V3</th><th align="left" id="dom12817-ent-0116" valign="bottom" rowspan="1" colspan="1"/><th colspan="2" align="left" id="dom12817-ent-0117" valign="bottom" rowspan="1">V2</th><th colspan="2" align="left" id="dom12817-ent-0118" valign="bottom" rowspan="1">V3</th><th align="left" id="dom12817-ent-0119" valign="bottom" rowspan="1" colspan="1"/><th colspan="2" align="left" id="dom12817-ent-0120" valign="bottom" rowspan="1">Linagliptin</th><th colspan="2" align="left" id="dom12817-ent-0121" valign="bottom" rowspan="1">Liraglutide</th><th align="center" id="dom12817-ent-0122" valign="bottom" rowspan="1" colspan="1"/></tr><tr style="border-bottom:solid 1px #000000"><th align="left" id="dom12817-ent-0123" valign="bottom" rowspan="1" colspan="1">Mean</th><th align="left" id="dom12817-ent-0124" valign="bottom" rowspan="1" colspan="1">S.E.</th><th align="left" id="dom12817-ent-0125" valign="bottom" rowspan="1" colspan="1">Mean</th><th align="left" id="dom12817-ent-0126" valign="bottom" rowspan="1" colspan="1">S.E.</th><th align="center" id="dom12817-ent-0127" valign="bottom" rowspan="1" colspan="1">
<italic>P</italic> value</th><th align="left" id="dom12817-ent-0128" valign="bottom" rowspan="1" colspan="1">Mean</th><th align="left" id="dom12817-ent-0129" valign="bottom" rowspan="1" colspan="1">S.E.</th><th align="left" id="dom12817-ent-0130" valign="bottom" rowspan="1" colspan="1">Mean</th><th align="left" id="dom12817-ent-0131" valign="bottom" rowspan="1" colspan="1">S.E.</th><th align="center" id="dom12817-ent-0132" valign="bottom" rowspan="1" colspan="1">
<italic>P</italic> value</th><th align="left" id="dom12817-ent-0133" valign="bottom" rowspan="1" colspan="1">Mean</th><th align="left" id="dom12817-ent-0134" valign="bottom" rowspan="1" colspan="1">S.E.</th><th align="left" id="dom12817-ent-0135" valign="bottom" rowspan="1" colspan="1">Mean</th><th align="left" id="dom12817-ent-0136" valign="bottom" rowspan="1" colspan="1">S.E.</th><th align="center" id="dom12817-ent-0137" valign="bottom" rowspan="1" colspan="1">
<italic>P</italic> value</th></tr></thead><tbody valign="top"><tr><td rowspan="2" align="left" id="dom12817-ent-0138" valign="top" colspan="1">ISR</td><td align="left" id="dom12817-ent-0139" valign="top" rowspan="1" colspan="1">
<italic>&#x00394;</italic>{225&#x02002;&#x02010;&#x02002;255}&#x02003;(pmol&#x0200a;/&#x0200a;m<sup>2</sup>)</td><td align="left" id="dom12817-ent-0140" valign="top" rowspan="1" colspan="1">&#x02212; 84.85</td><td align="left" id="dom12817-ent-0141" valign="top" rowspan="1" colspan="1">24.21</td><td align="left" id="dom12817-ent-0142" valign="top" rowspan="1" colspan="1">&#x02212; 105.90</td><td align="left" id="dom12817-ent-0143" valign="top" rowspan="1" colspan="1">17.37</td><td align="left" id="dom12817-ent-0144" valign="top" rowspan="1" colspan="1">.493</td><td align="left" id="dom12817-ent-0145" valign="top" rowspan="1" colspan="1">&#x02212; 105.70</td><td align="left" id="dom12817-ent-0146" valign="top" rowspan="1" colspan="1">23.42</td><td align="left" id="dom12817-ent-0147" valign="top" rowspan="1" colspan="1">&#x02212; 95.82</td><td align="left" id="dom12817-ent-0148" valign="top" rowspan="1" colspan="1">19.84</td><td align="left" id="dom12817-ent-0149" valign="top" rowspan="1" colspan="1">.733</td><td align="left" id="dom12817-ent-0150" valign="top" rowspan="1" colspan="1">&#x02212; 21.05</td><td align="left" id="dom12817-ent-0151" valign="top" rowspan="1" colspan="1">29.89</td><td align="left" id="dom12817-ent-0152" valign="top" rowspan="1" colspan="1">9.89</td><td align="left" id="dom12817-ent-0153" valign="top" rowspan="1" colspan="1">28.36</td><td align="left" id="dom12817-ent-0154" valign="top" rowspan="1" colspan="1">.461</td></tr><tr><td align="left" id="dom12817-ent-0155" valign="top" rowspan="1" colspan="1">AUC{225 &#x02010; 255}&#x02002;(pmol&#x0200a;/&#x0200a;m<sup>2</sup>&#x02002;&#x000d7;&#x02002;min)</td><td align="left" id="dom12817-ent-0156" valign="top" rowspan="1" colspan="1">2057.94</td><td align="left" id="dom12817-ent-0157" valign="top" rowspan="1" colspan="1">317.03</td><td align="left" id="dom12817-ent-0158" valign="top" rowspan="1" colspan="1">2010.04</td><td align="left" id="dom12817-ent-0159" valign="top" rowspan="1" colspan="1">250.84</td><td align="left" id="dom12817-ent-0160" valign="top" rowspan="1" colspan="1">.907</td><td align="left" id="dom12817-ent-0161" valign="top" rowspan="1" colspan="1">1824.22</td><td align="left" id="dom12817-ent-0162" valign="top" rowspan="1" colspan="1">283.26</td><td align="left" id="dom12817-ent-0163" valign="top" rowspan="1" colspan="1">2135.27</td><td align="left" id="dom12817-ent-0164" valign="top" rowspan="1" colspan="1">286.97</td><td align="left" id="dom12817-ent-0165" valign="top" rowspan="1" colspan="1">.463</td><td align="left" id="dom12817-ent-0166" valign="top" rowspan="1" colspan="1">&#x02212; 47.90</td><td align="left" id="dom12817-ent-0167" valign="top" rowspan="1" colspan="1">403.86</td><td align="left" id="dom12817-ent-0168" valign="top" rowspan="1" colspan="1">311.05</td><td align="left" id="dom12817-ent-0169" valign="top" rowspan="1" colspan="1">411.03</td><td align="left" id="dom12817-ent-0170" valign="top" rowspan="1" colspan="1">.539</td></tr><tr><td rowspan="2" align="left" id="dom12817-ent-0171" valign="top" colspan="1">Glucagon</td><td align="left" id="dom12817-ent-0172" valign="top" rowspan="1" colspan="1">
<italic>&#x00394;</italic>{225&#x02002;&#x02010;&#x02002;255}&#x02003;(pg&#x0200a;/&#x0200a;mL)</td><td align="left" id="dom12817-ent-0173" valign="top" rowspan="1" colspan="1">70.87</td><td align="left" id="dom12817-ent-0174" valign="top" rowspan="1" colspan="1">16.59</td><td align="left" id="dom12817-ent-0175" valign="top" rowspan="1" colspan="1">55.73</td><td align="left" id="dom12817-ent-0176" valign="top" rowspan="1" colspan="1">10.75</td><td align="left" id="dom12817-ent-0177" valign="top" rowspan="1" colspan="1">.393</td><td align="left" id="dom12817-ent-0178" valign="top" rowspan="1" colspan="1">56.43</td><td align="left" id="dom12817-ent-0179" valign="top" rowspan="1" colspan="1">12.24</td><td align="left" id="dom12817-ent-0180" valign="top" rowspan="1" colspan="1">62.21</td><td align="left" id="dom12817-ent-0181" valign="top" rowspan="1" colspan="1">13.25</td><td align="left" id="dom12817-ent-0182" valign="top" rowspan="1" colspan="1">.284</td><td align="left" id="dom12817-ent-0183" valign="top" rowspan="1" colspan="1">&#x02212; 15.13</td><td align="left" id="dom12817-ent-0184" valign="top" rowspan="1" colspan="1">17.16</td><td align="left" id="dom12817-ent-0185" valign="top" rowspan="1" colspan="1">5.79</td><td align="left" id="dom12817-ent-0186" valign="top" rowspan="1" colspan="1">5.18</td><td align="left" id="dom12817-ent-0187" valign="top" rowspan="1" colspan="1">.260</td></tr><tr><td align="left" id="dom12817-ent-0188" valign="top" rowspan="1" colspan="1">AUC{225 &#x02010; 300}&#x02002;(pg&#x0200a;/&#x0200a;mL&#x02002;&#x000d7;&#x02002;min)</td><td align="left" id="dom12817-ent-0189" valign="top" rowspan="1" colspan="1">9151.00</td><td align="left" id="dom12817-ent-0190" valign="top" rowspan="1" colspan="1">930.08</td><td align="left" id="dom12817-ent-0191" valign="top" rowspan="1" colspan="1">8653.50</td><td align="left" id="dom12817-ent-0192" valign="top" rowspan="1" colspan="1">700.72</td><td align="left" id="dom12817-ent-0193" valign="top" rowspan="1" colspan="1">.358</td><td align="left" id="dom12817-ent-0194" valign="top" rowspan="1" colspan="1">9051.43</td><td align="left" id="dom12817-ent-0195" valign="top" rowspan="1" colspan="1">787.85</td><td align="left" id="dom12817-ent-0196" valign="top" rowspan="1" colspan="1">8776.61</td><td align="left" id="dom12817-ent-0197" valign="top" rowspan="1" colspan="1">786.45</td><td align="left" id="dom12817-ent-0198" valign="top" rowspan="1" colspan="1">.226</td><td align="left" id="dom12817-ent-0199" valign="top" rowspan="1" colspan="1">&#x02212; 497.50</td><td align="left" id="dom12817-ent-0200" valign="top" rowspan="1" colspan="1">523.15</td><td align="left" id="dom12817-ent-0201" valign="top" rowspan="1" colspan="1">&#x02212; 274.82</td><td align="left" id="dom12817-ent-0202" valign="top" rowspan="1" colspan="1">216.39</td><td align="left" id="dom12817-ent-0203" valign="top" rowspan="1" colspan="1">.699</td></tr><tr><td rowspan="2" align="left" id="dom12817-ent-0204" valign="top" colspan="1">Growth hormone</td><td align="left" id="dom12817-ent-0205" valign="top" rowspan="1" colspan="1">
<italic>&#x00394;</italic>{225&#x02002;&#x02010;&#x02002;255}&#x02003;(ng&#x0200a;/&#x0200a;mL)</td><td align="left" id="dom12817-ent-0206" valign="top" rowspan="1" colspan="1">5.07</td><td align="left" id="dom12817-ent-0207" valign="top" rowspan="1" colspan="1">1.04</td><td align="left" id="dom12817-ent-0208" valign="top" rowspan="1" colspan="1">2.48</td><td align="left" id="dom12817-ent-0209" valign="top" rowspan="1" colspan="1">0.87</td><td align="left" id="dom12817-ent-0210" valign="top" rowspan="1" colspan="1">.023</td><td align="left" id="dom12817-ent-0211" valign="top" rowspan="1" colspan="1">2.58</td><td align="left" id="dom12817-ent-0212" valign="top" rowspan="1" colspan="1">0.80</td><td align="left" id="dom12817-ent-0213" valign="top" rowspan="1" colspan="1">0.94</td><td align="left" id="dom12817-ent-0214" valign="top" rowspan="1" colspan="1">0.39</td><td align="left" id="dom12817-ent-0215" valign="top" rowspan="1" colspan="1">.081</td><td align="left" id="dom12817-ent-0216" valign="top" rowspan="1" colspan="1">&#x02212; 2.60</td><td align="left" id="dom12817-ent-0217" valign="top" rowspan="1" colspan="1">1.01</td><td align="left" id="dom12817-ent-0218" valign="top" rowspan="1" colspan="1">&#x02212; 1.65</td><td align="left" id="dom12817-ent-0219" valign="top" rowspan="1" colspan="1">0.87</td><td align="left" id="dom12817-ent-0220" valign="top" rowspan="1" colspan="1">.486</td></tr><tr><td align="left" id="dom12817-ent-0221" valign="top" rowspan="1" colspan="1">AUC{225 &#x02010; 300}&#x02002;(ng&#x0200a;/&#x0200a;mL&#x02002;&#x000d7;&#x02002;min)</td><td align="left" id="dom12817-ent-0222" valign="top" rowspan="1" colspan="1">329.10</td><td align="left" id="dom12817-ent-0223" valign="top" rowspan="1" colspan="1">45.03</td><td align="left" id="dom12817-ent-0224" valign="top" rowspan="1" colspan="1">256.65</td><td align="left" id="dom12817-ent-0225" valign="top" rowspan="1" colspan="1">48.81</td><td align="left" id="dom12817-ent-0226" valign="top" rowspan="1" colspan="1">.222</td><td align="left" id="dom12817-ent-0227" valign="top" rowspan="1" colspan="1">275.08</td><td align="left" id="dom12817-ent-0228" valign="top" rowspan="1" colspan="1">49.58</td><td align="left" id="dom12817-ent-0229" valign="top" rowspan="1" colspan="1">219.30</td><td align="left" id="dom12817-ent-0230" valign="top" rowspan="1" colspan="1">47.28</td><td align="left" id="dom12817-ent-0231" valign="top" rowspan="1" colspan="1">.264</td><td align="left" id="dom12817-ent-0232" valign="top" rowspan="1" colspan="1">&#x02212; 72.44</td><td align="left" id="dom12817-ent-0233" valign="top" rowspan="1" colspan="1">56.62</td><td align="left" id="dom12817-ent-0234" valign="top" rowspan="1" colspan="1">&#x02212; 55.78</td><td align="left" id="dom12817-ent-0235" valign="top" rowspan="1" colspan="1">47.72</td><td align="left" id="dom12817-ent-0236" valign="top" rowspan="1" colspan="1">.825</td></tr><tr><td rowspan="2" align="left" id="dom12817-ent-0237" valign="top" colspan="1">Cortisol</td><td align="left" id="dom12817-ent-0238" valign="top" rowspan="1" colspan="1">
<italic>&#x00394;</italic>{225&#x02002;&#x02010;&#x02002;255}&#x02003;(&#x000b5;g&#x0200a;/&#x0200a;dL)</td><td align="left" id="dom12817-ent-0239" valign="top" rowspan="1" colspan="1">7.09</td><td align="left" id="dom12817-ent-0240" valign="top" rowspan="1" colspan="1">1.49</td><td align="left" id="dom12817-ent-0241" valign="top" rowspan="1" colspan="1">3.05</td><td align="left" id="dom12817-ent-0242" valign="top" rowspan="1" colspan="1">1.12</td><td align="left" id="dom12817-ent-0243" valign="top" rowspan="1" colspan="1">.035</td><td align="left" id="dom12817-ent-0244" valign="top" rowspan="1" colspan="1">3.34</td><td align="left" id="dom12817-ent-0245" valign="top" rowspan="1" colspan="1">1.47</td><td align="left" id="dom12817-ent-0246" valign="top" rowspan="1" colspan="1">1.51</td><td align="left" id="dom12817-ent-0247" valign="top" rowspan="1" colspan="1">0.96</td><td align="left" id="dom12817-ent-0248" valign="top" rowspan="1" colspan="1">.315</td><td align="left" id="dom12817-ent-0249" valign="top" rowspan="1" colspan="1">&#x02212; 4.05</td><td align="left" id="dom12817-ent-0250" valign="top" rowspan="1" colspan="1">1.74</td><td align="left" id="dom12817-ent-0251" valign="top" rowspan="1" colspan="1">&#x02212; 1.83</td><td align="left" id="dom12817-ent-0252" valign="top" rowspan="1" colspan="1">1.75</td><td align="left" id="dom12817-ent-0253" valign="top" rowspan="1" colspan="1">.377</td></tr><tr><td align="left" id="dom12817-ent-0254" valign="top" rowspan="1" colspan="1">AUC{225 &#x02010; 300}&#x02002;(&#x000b5;g&#x0200a;/&#x0200a;dL&#x02002;&#x000d7;&#x02002;min)</td><td align="left" id="dom12817-ent-0255" valign="top" rowspan="1" colspan="1">1302.25</td><td align="left" id="dom12817-ent-0256" valign="top" rowspan="1" colspan="1">71.33</td><td align="left" id="dom12817-ent-0257" valign="top" rowspan="1" colspan="1">970.80</td><td align="left" id="dom12817-ent-0258" valign="top" rowspan="1" colspan="1">65.19</td><td align="left" id="dom12817-ent-0259" valign="top" rowspan="1" colspan="1">.000</td><td align="left" id="dom12817-ent-0260" valign="top" rowspan="1" colspan="1">1225.45</td><td align="left" id="dom12817-ent-0261" valign="top" rowspan="1" colspan="1">103.09</td><td align="left" id="dom12817-ent-0262" valign="top" rowspan="1" colspan="1">907.61</td><td align="left" id="dom12817-ent-0263" valign="top" rowspan="1" colspan="1">64.00</td><td align="left" id="dom12817-ent-0264" valign="top" rowspan="1" colspan="1">.001</td><td align="left" id="dom12817-ent-0265" valign="top" rowspan="1" colspan="1">&#x02212; 331.45</td><td align="left" id="dom12817-ent-0266" valign="top" rowspan="1" colspan="1">68.13</td><td align="left" id="dom12817-ent-0267" valign="top" rowspan="1" colspan="1">&#x02212; 317.84</td><td align="left" id="dom12817-ent-0268" valign="top" rowspan="1" colspan="1">77.99</td><td align="left" id="dom12817-ent-0269" valign="top" rowspan="1" colspan="1">.896</td></tr><tr><td rowspan="2" align="left" id="dom12817-ent-0270" valign="top" colspan="1">Epinephrine</td><td align="left" id="dom12817-ent-0271" valign="top" rowspan="1" colspan="1">
<italic>&#x00394;</italic>{225&#x02002;&#x02010;&#x02002;255}&#x02003;(ng&#x0200a;/&#x0200a;mL)</td><td align="left" id="dom12817-ent-0272" valign="top" rowspan="1" colspan="1">0.98</td><td align="left" id="dom12817-ent-0273" valign="top" rowspan="1" colspan="1">0.22</td><td align="left" id="dom12817-ent-0274" valign="top" rowspan="1" colspan="1">0.53</td><td align="left" id="dom12817-ent-0275" valign="top" rowspan="1" colspan="1">0.14</td><td align="left" id="dom12817-ent-0276" valign="top" rowspan="1" colspan="1">.103</td><td align="left" id="dom12817-ent-0277" valign="top" rowspan="1" colspan="1">0.72</td><td align="left" id="dom12817-ent-0278" valign="top" rowspan="1" colspan="1">0.20</td><td align="left" id="dom12817-ent-0279" valign="top" rowspan="1" colspan="1">0.33</td><td align="left" id="dom12817-ent-0280" valign="top" rowspan="1" colspan="1">0.09</td><td align="left" id="dom12817-ent-0281" valign="top" rowspan="1" colspan="1">.091</td><td align="left" id="dom12817-ent-0282" valign="top" rowspan="1" colspan="1">&#x02212; 0.45</td><td align="left" id="dom12817-ent-0283" valign="top" rowspan="1" colspan="1">0.16</td><td align="left" id="dom12817-ent-0284" valign="top" rowspan="1" colspan="1">&#x02212; 0.39</td><td align="left" id="dom12817-ent-0285" valign="top" rowspan="1" colspan="1">0.12</td><td align="left" id="dom12817-ent-0286" valign="top" rowspan="1" colspan="1">.769</td></tr><tr><td align="left" id="dom12817-ent-0287" valign="top" rowspan="1" colspan="1">AUC{225 &#x02010; 300}&#x02002;(ng&#x0200a;/&#x0200a;mL&#x02002;&#x000d7;&#x02002;min)</td><td align="left" id="dom12817-ent-0288" valign="top" rowspan="1" colspan="1">36.25</td><td align="left" id="dom12817-ent-0289" valign="top" rowspan="1" colspan="1">7.56</td><td align="left" id="dom12817-ent-0290" valign="top" rowspan="1" colspan="1">20.25</td><td align="left" id="dom12817-ent-0291" valign="top" rowspan="1" colspan="1">3.60</td><td align="left" id="dom12817-ent-0292" valign="top" rowspan="1" colspan="1">.006</td><td align="left" id="dom12817-ent-0293" valign="top" rowspan="1" colspan="1">28.23</td><td align="left" id="dom12817-ent-0294" valign="top" rowspan="1" colspan="1">6.19</td><td align="left" id="dom12817-ent-0295" valign="top" rowspan="1" colspan="1">13.23</td><td align="left" id="dom12817-ent-0296" valign="top" rowspan="1" colspan="1">2.25</td><td align="left" id="dom12817-ent-0297" valign="top" rowspan="1" colspan="1">.004</td><td align="left" id="dom12817-ent-0298" valign="top" rowspan="1" colspan="1">&#x02212; 16.00</td><td align="left" id="dom12817-ent-0299" valign="top" rowspan="1" colspan="1">4.92</td><td align="left" id="dom12817-ent-0300" valign="top" rowspan="1" colspan="1">&#x02212; 15.00</td><td align="left" id="dom12817-ent-0301" valign="top" rowspan="1" colspan="1">4.35</td><td align="left" id="dom12817-ent-0302" valign="top" rowspan="1" colspan="1">.881</td></tr><tr><td rowspan="2" align="left" id="dom12817-ent-0303" valign="top" colspan="1">Norepinephrine</td><td align="left" id="dom12817-ent-0304" valign="top" rowspan="1" colspan="1">
<italic>&#x00394;</italic>{225&#x02002;&#x02010;&#x02002;255}&#x02003;(ng&#x0200a;/&#x0200a;mL)</td><td align="left" id="dom12817-ent-0305" valign="top" rowspan="1" colspan="1">0.29</td><td align="left" id="dom12817-ent-0306" valign="top" rowspan="1" colspan="1">0.07</td><td align="left" id="dom12817-ent-0307" valign="top" rowspan="1" colspan="1">0.14</td><td align="left" id="dom12817-ent-0308" valign="top" rowspan="1" colspan="1">0.04</td><td align="left" id="dom12817-ent-0309" valign="top" rowspan="1" colspan="1">.041</td><td align="left" id="dom12817-ent-0310" valign="top" rowspan="1" colspan="1">0.23</td><td align="left" id="dom12817-ent-0311" valign="top" rowspan="1" colspan="1">0.05</td><td align="left" id="dom12817-ent-0312" valign="top" rowspan="1" colspan="1">0.15</td><td align="left" id="dom12817-ent-0313" valign="top" rowspan="1" colspan="1">0.04</td><td align="left" id="dom12817-ent-0314" valign="top" rowspan="1" colspan="1">.079</td><td align="left" id="dom12817-ent-0315" valign="top" rowspan="1" colspan="1">&#x02212; 0.15</td><td align="left" id="dom12817-ent-0316" valign="top" rowspan="1" colspan="1">0.06</td><td align="left" id="dom12817-ent-0317" valign="top" rowspan="1" colspan="1">&#x02212; 0.08</td><td align="left" id="dom12817-ent-0318" valign="top" rowspan="1" colspan="1">0.04</td><td align="left" id="dom12817-ent-0319" valign="top" rowspan="1" colspan="1">.422</td></tr><tr><td align="left" id="dom12817-ent-0320" valign="top" rowspan="1" colspan="1">AUC{225 &#x02010; 300}&#x02002;(ng&#x0200a;/&#x0200a;mL&#x02002;&#x000d7;&#x02002;min)</td><td align="left" id="dom12817-ent-0321" valign="top" rowspan="1" colspan="1">30.09</td><td align="left" id="dom12817-ent-0322" valign="top" rowspan="1" colspan="1">3.37</td><td align="left" id="dom12817-ent-0323" valign="top" rowspan="1" colspan="1">27.90</td><td align="left" id="dom12817-ent-0324" valign="top" rowspan="1" colspan="1">2.02</td><td align="left" id="dom12817-ent-0325" valign="top" rowspan="1" colspan="1">.277</td><td align="left" id="dom12817-ent-0326" valign="top" rowspan="1" colspan="1">29.76</td><td align="left" id="dom12817-ent-0327" valign="top" rowspan="1" colspan="1">2.19</td><td align="left" id="dom12817-ent-0328" valign="top" rowspan="1" colspan="1">27.96</td><td align="left" id="dom12817-ent-0329" valign="top" rowspan="1" colspan="1">1.78</td><td align="left" id="dom12817-ent-0330" valign="top" rowspan="1" colspan="1">.313</td><td align="left" id="dom12817-ent-0331" valign="top" rowspan="1" colspan="1">&#x02212; 2.19</td><td align="left" id="dom12817-ent-0332" valign="top" rowspan="1" colspan="1">1.93</td><td align="left" id="dom12817-ent-0333" valign="top" rowspan="1" colspan="1">&#x02212; 1.80</td><td align="left" id="dom12817-ent-0334" valign="top" rowspan="1" colspan="1">1.72</td><td align="left" id="dom12817-ent-0335" valign="top" rowspan="1" colspan="1">.883</td></tr><tr><td rowspan="2" align="left" id="dom12817-ent-0336" valign="top" colspan="1">Total GIP</td><td align="left" id="dom12817-ent-0337" valign="top" rowspan="1" colspan="1">
<italic>&#x00394;</italic>{225&#x02002;&#x02010;&#x02002;255}&#x02003;(pmol&#x0200a;/&#x0200a;L)</td><td align="left" id="dom12817-ent-0338" valign="top" rowspan="1" colspan="1">67.07</td><td align="left" id="dom12817-ent-0339" valign="top" rowspan="1" colspan="1">35.14</td><td align="left" id="dom12817-ent-0340" valign="top" rowspan="1" colspan="1">60.08</td><td align="left" id="dom12817-ent-0341" valign="top" rowspan="1" colspan="1">23.76</td><td align="left" id="dom12817-ent-0342" valign="top" rowspan="1" colspan="1">.871</td><td align="left" id="dom12817-ent-0343" valign="top" rowspan="1" colspan="1">&#x02212; 66.22</td><td align="left" id="dom12817-ent-0344" valign="top" rowspan="1" colspan="1">58.52</td><td align="left" id="dom12817-ent-0345" valign="top" rowspan="1" colspan="1">&#x02212; 29.28</td><td align="left" id="dom12817-ent-0346" valign="top" rowspan="1" colspan="1">29.28</td><td align="left" id="dom12817-ent-0347" valign="top" rowspan="1" colspan="1">.579</td><td align="left" id="dom12817-ent-0348" valign="top" rowspan="1" colspan="1">&#x02212; 6.98</td><td align="left" id="dom12817-ent-0349" valign="top" rowspan="1" colspan="1">34.20</td><td align="left" id="dom12817-ent-0350" valign="top" rowspan="1" colspan="1">36.94</td><td align="left" id="dom12817-ent-0351" valign="top" rowspan="1" colspan="1">48.61</td><td align="left" id="dom12817-ent-0352" valign="top" rowspan="1" colspan="1">.452</td></tr><tr><td align="left" id="dom12817-ent-0353" valign="top" rowspan="1" colspan="1">AUC{225 &#x02010; 300}&#x02002;(pmol&#x0200a;/&#x0200a;L&#x02002;&#x000d7;&#x02002;min)</td><td align="left" id="dom12817-ent-0354" valign="top" rowspan="1" colspan="1">14196.60</td><td align="left" id="dom12817-ent-0355" valign="top" rowspan="1" colspan="1">2810.26</td><td align="left" id="dom12817-ent-0356" valign="top" rowspan="1" colspan="1">13006.23</td><td align="left" id="dom12817-ent-0357" valign="top" rowspan="1" colspan="1">1441.86</td><td align="left" id="dom12817-ent-0358" valign="top" rowspan="1" colspan="1">.620</td><td align="left" id="dom12817-ent-0359" valign="top" rowspan="1" colspan="1">9828.73</td><td align="left" id="dom12817-ent-0360" valign="top" rowspan="1" colspan="1">766.24</td><td align="left" id="dom12817-ent-0361" valign="top" rowspan="1" colspan="1">14330.31</td><td align="left" id="dom12817-ent-0362" valign="top" rowspan="1" colspan="1">1533.50</td><td align="left" id="dom12817-ent-0363" valign="top" rowspan="1" colspan="1">.014</td><td align="left" id="dom12817-ent-0364" valign="top" rowspan="1" colspan="1">&#x02212; 1190.37</td><td align="left" id="dom12817-ent-0365" valign="top" rowspan="1" colspan="1">2349.66</td><td align="left" id="dom12817-ent-0366" valign="top" rowspan="1" colspan="1">4501.58</td><td align="left" id="dom12817-ent-0367" valign="top" rowspan="1" colspan="1">1581.68</td><td align="left" id="dom12817-ent-0368" valign="top" rowspan="1" colspan="1">.058</td></tr><tr><td rowspan="2" align="left" id="dom12817-ent-0369" valign="top" colspan="1">Intact GIP</td><td align="left" id="dom12817-ent-0370" valign="top" rowspan="1" colspan="1">
<italic>&#x00394;</italic>{225&#x02002;&#x02010;&#x02002;255}&#x02003;(pmol&#x0200a;/&#x0200a;L)</td><td align="left" id="dom12817-ent-0371" valign="top" rowspan="1" colspan="1">9.17</td><td align="left" id="dom12817-ent-0372" valign="top" rowspan="1" colspan="1">5.50</td><td align="left" id="dom12817-ent-0373" valign="top" rowspan="1" colspan="1">11.71</td><td align="left" id="dom12817-ent-0374" valign="top" rowspan="1" colspan="1">6.34</td><td align="left" id="dom12817-ent-0375" valign="top" rowspan="1" colspan="1">.765</td><td align="left" id="dom12817-ent-0376" valign="top" rowspan="1" colspan="1">&#x02212; 8.04</td><td align="left" id="dom12817-ent-0377" valign="top" rowspan="1" colspan="1">8.08</td><td align="left" id="dom12817-ent-0378" valign="top" rowspan="1" colspan="1">0.13</td><td align="left" id="dom12817-ent-0379" valign="top" rowspan="1" colspan="1">5.57</td><td align="left" id="dom12817-ent-0380" valign="top" rowspan="1" colspan="1">.413</td><td align="left" id="dom12817-ent-0381" valign="top" rowspan="1" colspan="1">2.54</td><td align="left" id="dom12817-ent-0382" valign="top" rowspan="1" colspan="1">7.37</td><td align="left" id="dom12817-ent-0383" valign="top" rowspan="1" colspan="1">8.17</td><td align="left" id="dom12817-ent-0384" valign="top" rowspan="1" colspan="1">7.06</td><td align="left" id="dom12817-ent-0385" valign="top" rowspan="1" colspan="1">.587</td></tr><tr><td align="left" id="dom12817-ent-0386" valign="top" rowspan="1" colspan="1">AUC{225 &#x02010; 300}&#x02002;(pmol&#x0200a;/&#x0200a;L&#x02002;&#x000d7;&#x02002;min)</td><td align="left" id="dom12817-ent-0387" valign="top" rowspan="1" colspan="1">1434.30</td><td align="left" id="dom12817-ent-0388" valign="top" rowspan="1" colspan="1">296.39</td><td align="left" id="dom12817-ent-0389" valign="top" rowspan="1" colspan="1">3386.85</td><td align="left" id="dom12817-ent-0390" valign="top" rowspan="1" colspan="1">436.02</td><td align="left" id="dom12817-ent-0391" valign="top" rowspan="1" colspan="1">&#x0003c;.0001</td><td align="left" id="dom12817-ent-0392" valign="top" rowspan="1" colspan="1">1096.42</td><td align="left" id="dom12817-ent-0393" valign="top" rowspan="1" colspan="1">150.22</td><td align="left" id="dom12817-ent-0394" valign="top" rowspan="1" colspan="1">1528.59</td><td align="left" id="dom12817-ent-0395" valign="top" rowspan="1" colspan="1">173.40</td><td align="left" id="dom12817-ent-0396" valign="top" rowspan="1" colspan="1">.065</td><td align="left" id="dom12817-ent-0397" valign="top" rowspan="1" colspan="1">1952.55</td><td align="left" id="dom12817-ent-0398" valign="top" rowspan="1" colspan="1">335.06</td><td align="left" id="dom12817-ent-0399" valign="top" rowspan="1" colspan="1">432.17</td><td align="left" id="dom12817-ent-0400" valign="top" rowspan="1" colspan="1">214.47</td><td align="left" id="dom12817-ent-0401" valign="top" rowspan="1" colspan="1">.001</td></tr><tr><td rowspan="2" align="left" id="dom12817-ent-0402" valign="top" colspan="1">Total GLP&#x02010;1</td><td align="left" id="dom12817-ent-0403" valign="top" rowspan="1" colspan="1">
<italic>&#x00394;</italic>{225&#x02002;&#x02010;&#x02002;255}&#x02003;(pmol&#x0200a;/&#x0200a;L)</td><td align="left" id="dom12817-ent-0404" valign="top" rowspan="1" colspan="1">2.19</td><td align="left" id="dom12817-ent-0405" valign="top" rowspan="1" colspan="1">0.71</td><td align="left" id="dom12817-ent-0406" valign="top" rowspan="1" colspan="1">2.50</td><td align="left" id="dom12817-ent-0407" valign="top" rowspan="1" colspan="1">1.00</td><td align="left" id="dom12817-ent-0408" valign="top" rowspan="1" colspan="1">.804</td><td colspan="2" align="center" id="dom12817-ent-0409" valign="top" rowspan="1">ND</td><td colspan="2" align="center" id="dom12817-ent-0410" valign="top" rowspan="1">ND</td><td align="left" id="dom12817-ent-0411" valign="top" rowspan="1" colspan="1"/><td align="left" id="dom12817-ent-0412" valign="top" rowspan="1" colspan="1">0.31</td><td align="left" id="dom12817-ent-0413" valign="top" rowspan="1" colspan="1">0.92</td><td colspan="2" align="center" id="dom12817-ent-0414" valign="top" rowspan="1">ND</td><td align="left" id="dom12817-ent-0415" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" id="dom12817-ent-0416" valign="top" rowspan="1" colspan="1">AUC{225 &#x02010; 300}&#x02002;(pmol&#x0200a;/&#x0200a;L&#x02002;&#x000d7;&#x02002;min)</td><td align="left" id="dom12817-ent-0417" valign="top" rowspan="1" colspan="1">433.04</td><td align="left" id="dom12817-ent-0418" valign="top" rowspan="1" colspan="1">45.82</td><td align="left" id="dom12817-ent-0419" valign="top" rowspan="1" colspan="1">430.15</td><td align="left" id="dom12817-ent-0420" valign="top" rowspan="1" colspan="1">41.01</td><td align="left" id="dom12817-ent-0421" valign="top" rowspan="1" colspan="1">.923</td><td colspan="2" align="left" id="dom12817-ent-0422" valign="top" rowspan="1"/><td colspan="2" align="left" id="dom12817-ent-0423" valign="top" rowspan="1"/><td align="left" id="dom12817-ent-0424" valign="top" rowspan="1" colspan="1"/><td align="left" id="dom12817-ent-0425" valign="top" rowspan="1" colspan="1">&#x02212; 2.89</td><td align="left" id="dom12817-ent-0426" valign="top" rowspan="1" colspan="1">29.34</td><td colspan="2" align="center" id="dom12817-ent-0427" valign="top" rowspan="1">ND</td><td align="left" id="dom12817-ent-0428" valign="top" rowspan="1" colspan="1"/></tr><tr><td rowspan="2" align="left" id="dom12817-ent-0429" valign="top" colspan="1">Intact GLP&#x02010;1</td><td align="left" id="dom12817-ent-0430" valign="top" rowspan="1" colspan="1">
<italic>&#x00394;</italic>{225&#x02002;&#x02010;&#x02002;255}&#x02003;(pmol&#x0200a;/&#x0200a;L)</td><td align="left" id="dom12817-ent-0431" valign="top" rowspan="1" colspan="1">&#x02212; 0.71</td><td align="left" id="dom12817-ent-0432" valign="top" rowspan="1" colspan="1">0.26</td><td align="left" id="dom12817-ent-0433" valign="top" rowspan="1" colspan="1">0.61</td><td align="left" id="dom12817-ent-0434" valign="top" rowspan="1" colspan="1">0.69</td><td align="left" id="dom12817-ent-0435" valign="top" rowspan="1" colspan="1">.091</td><td colspan="2" align="center" id="dom12817-ent-0436" valign="top" rowspan="1">ND</td><td colspan="2" align="center" id="dom12817-ent-0437" valign="top" rowspan="1">ND</td><td align="left" id="dom12817-ent-0438" valign="top" rowspan="1" colspan="1"/><td align="left" id="dom12817-ent-0439" valign="top" rowspan="1" colspan="1">1.32</td><td align="left" id="dom12817-ent-0440" valign="top" rowspan="1" colspan="1">0.70</td><td colspan="2" align="center" id="dom12817-ent-0441" valign="top" rowspan="1">ND</td><td align="left" id="dom12817-ent-0442" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" id="dom12817-ent-0443" valign="top" rowspan="1" colspan="1">AUC{225 &#x02010; 300}&#x02002;(pmol&#x0200a;/&#x0200a;L&#x02002;&#x000d7;&#x02002;min)</td><td align="left" id="dom12817-ent-0444" valign="top" rowspan="1" colspan="1">95.23</td><td align="left" id="dom12817-ent-0445" valign="top" rowspan="1" colspan="1">10.54</td><td align="left" id="dom12817-ent-0446" valign="top" rowspan="1" colspan="1">225.71</td><td align="left" id="dom12817-ent-0447" valign="top" rowspan="1" colspan="1">20.42</td><td align="left" id="dom12817-ent-0448" valign="top" rowspan="1" colspan="1">&#x0003c;.0001</td><td colspan="2" align="center" id="dom12817-ent-0449" valign="top" rowspan="1">ND</td><td colspan="2" align="center" id="dom12817-ent-0450" valign="top" rowspan="1">ND</td><td align="left" id="dom12817-ent-0451" valign="top" rowspan="1" colspan="1"/><td align="left" id="dom12817-ent-0452" valign="top" rowspan="1" colspan="1">130.48</td><td align="left" id="dom12817-ent-0453" valign="top" rowspan="1" colspan="1">18.94</td><td colspan="2" align="center" id="dom12817-ent-0454" valign="top" rowspan="1">ND</td><td align="left" id="dom12817-ent-0455" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="dom12817-note-0005"><p>Abbreviations: <styled-content style="fixed-case">AUC</styled-content>, area under the curve; <styled-content style="fixed-case">CPR</styled-content>, C&#x02010;peptide reactivity; <styled-content style="fixed-case">GIP</styled-content>, glucose&#x02010;dependent insulinotropic polypeptide; <styled-content style="fixed-case">GLP</styled-content>&#x02010;1, glucagon&#x02010;like peptide&#x02010;1; <styled-content style="fixed-case">ISR</styled-content>, insulin secretion rate; <styled-content style="fixed-case">S.E.</styled-content>, standard error; V2, visit 2; V3, visit3.</p></fn></table-wrap-foot></table-wrap><sec id="dom12817-sec-0008"><label>3.1</label><title>Safety</title><p id="dom12817-para-0010">AE and SAE were analysed in the FAS population. No AE was reported in the linagliptin group. One subject in the liraglutide group experienced nausea, which was assessed as non&#x02010;serious and treatment&#x02010;related. No SAE was experienced by any individual in either group.</p></sec></sec><sec id="dom12817-sec-0009"><label>4</label><title>DISCUSSION</title><p id="dom12817-para-0011">A main finding of this study comparing linagliptin with liraglutide in Japanese individuals with T2D confirms our general understanding that incretin therapies do not prevent hypoglycaemia&#x02010;induced glucagon secretion, as was previously reported for the DPP&#x02010;4 inhibitor vildagliptin and the GLP&#x02010;1R agonists albiglutide and lixisenatide in individuals with T2D.<xref rid="dom12817-bib-0011" ref-type="ref">11</xref>, <xref rid="dom12817-bib-0012" ref-type="ref">12</xref>, <xref rid="dom12817-bib-0013" ref-type="ref">13</xref>, <xref rid="dom12817-bib-0014" ref-type="ref">14</xref> This supports the notion that these therapies are not associated with increased risk of hypoglycaemia. Importantly, the present study shows that linagliptin did not enhance hypoglycaemia&#x02010;induced glucagon secretion even though biologically intact GIP was significantly elevated. It has been shown previously that vildagliptin enhanced hypoglycaemia&#x02010;induced glucagon secretion in drug&#x02010;naive individuals with T2.<xref rid="dom12817-bib-0011" ref-type="ref">11</xref> Discrepancies between that study and ours could be explained by the following possibilities. First, different DPP&#x02010;4 inhibitors were used for different treatment periods (ie, vildagliptin, 4 weeks; linagliptin, 2 weeks). Second, different comparisons were made (ie, vildagliptin vs placebo; linagliptin vs liraglutide; before vs after linagliptin treatment). Third, different ethnic groups were studied (ie, Caucasian vs Japanese); T2D in East Asians, including Japanese, is characterized primarily by &#x003b2;&#x02010;cell dysfunction with less adiposity and it differs phenotypically from T2D in Caucasians,<xref rid="dom12817-bib-0015" ref-type="ref">15</xref> showing greater HbA1c reduction in response to DPP&#x02010;4 inhibitors and GLP&#x02010;1R agonists.<xref rid="dom12817-bib-0016" ref-type="ref">16</xref>, <xref rid="dom12817-bib-0017" ref-type="ref">17</xref> Finally, subjects with different baseline HbA1c levels were enrolled (ie, mean HbA1c 6.3% vs 7.3%). It could therefore be possible that glucagonotropic effects of GIP might be impaired by chronic hyperglycaemia, similarly to the insulinotropic effects of GIP.<xref rid="dom12817-bib-0018" ref-type="ref">18</xref> Interestingly, enhancement of the hypoglycaemia&#x02010;induced glucagon response by GIP or vildagliptin was observed in T2D individuals with mean baseline HbA1c values between 6.3% and 6.5%,<xref rid="dom12817-bib-0007" ref-type="ref">7</xref>, <xref rid="dom12817-bib-0011" ref-type="ref">11</xref> but there was little enhancement by vildagliptin in individuals with T2D with a mean baseline HbA1c value of 7.7%.<xref rid="dom12817-bib-0014" ref-type="ref">14</xref> Further investigations are required to clarify the discrepancies between these two studies.</p><p id="dom12817-para-0012">In the current study, the hypoglycaemia&#x02010;induced responses of the counter&#x02010;regulatory hormones GH, cortisol, epinephrine and norepinephrine were attenuated at V3 compared to those at V2, which is similar to the effect of DPP&#x02010;4 inhibitor linagliptin and the GLP&#x02010;1 receptor agonist liraglutide (Table <xref rid="dom12817-tbl-0002" ref-type="table-wrap">2</xref> and Figure S6). The lack of placebo or euglycaemic control groups in our study does not permit exclusion of the possibility that the subjects&#x02019; experiences at V2 might affect the counter&#x02010;responses of GH, cortisol, epinephrine and norepinephrine seen at V3. Furthermore, the variable IIR could result in different insulin levels between tests that might affect responses of the counter&#x02010;regulatory hormones. However, a recent study in T2D individuals reported suppressive effects on hypoglycaemia&#x02010;induced sympatho&#x02010;adrenal response after treatment with the GLP&#x02010;1 receptor agonist lixisenatide,<xref rid="dom12817-bib-0013" ref-type="ref">13</xref> which are similar to our present findings. Co&#x02010;administration of some incretin therapies in insulin and/or sulfonylurea&#x02010;treated individuals with T2D would seem to have potential for preventing hypoglycaemia&#x02010;induced release of cortisol and catecholamine, and thus possibly reduce cardiovascular event risks. However, further investigations are needed to clarify the underlying mechanisms and clinical relevance of the current findings, as most previous studies on incretin therapies did not show similar suppressive effects in individuals with T2D or type 1 diabetes.<xref rid="dom12817-bib-0011" ref-type="ref">11</xref>, <xref rid="dom12817-bib-0019" ref-type="ref">19</xref>, <xref rid="dom12817-bib-0020" ref-type="ref">20</xref> In conclusion, neither the DPP&#x02010;4 inhibitor linagliptin nor the GLP&#x02010;1 receptor agonist liraglutide impaired the alpha&#x02010;cell responsiveness to hypoglycaemia in Japanese individuals with T2D.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="dom12817-supitem-0001"><caption><p>
<bold>Figure S1</bold>. <styled-content style="fixed-case">CONSORT</styled-content> Flow diagram of the study.</p></caption><media xlink:href="DOM-19-442-s005.pptx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="dom12817-supitem-0002"><caption><p>
<bold>Figure S2</bold>. Glucose, C&#x02010;peptide, insulin secretion rate (<styled-content style="fixed-case">ISR</styled-content>) and glucagon during meal tolerance tests in the per protocol population.</p></caption><media xlink:href="DOM-19-442-s004.pptx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="dom12817-supitem-0003"><caption><p>
<bold>Figure S3</bold>. Glucose&#x02010;dependent insulinotropic polypeptide (<styled-content style="fixed-case">GIP</styled-content>) and glucagon&#x02010;like peptide&#x02010;1 (<styled-content style="fixed-case">GLP</styled-content>&#x02010;1) during meal tolerance tests in the per protocol population.</p></caption><media xlink:href="DOM-19-442-s003.pptx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="dom12817-supitem-0004"><caption><p>
<bold>Figure S4</bold>. Glucose, C&#x02010;peptide, insulin secretion rate (<styled-content style="fixed-case">ISR</styled-content>) and insulin infusion rate (<styled-content style="fixed-case">IIR</styled-content>) during three&#x02010;step hyperinsulinemic clamp tests in the per protocol population.</p></caption><media xlink:href="DOM-19-442-s009.pptx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="dom12817-supitem-0005"><caption><p>
<bold>Figure S5</bold>. Glucagon, glucose&#x02010;dependent insulinotropic polypeptide (<styled-content style="fixed-case">GIP</styled-content>) and glucagon&#x02010;like peptide&#x02010;1 (<styled-content style="fixed-case">GLP</styled-content>&#x02010;1) during three&#x02010;step hyperinsulinemic clamp tests in the per protocol population.</p></caption><media xlink:href="DOM-19-442-s006.pptx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="dom12817-supitem-0006"><caption><p>
<bold>Figure S6</bold>. Growth hormone, cortisol, norepinephrine and epinephrine during hyperinsulinemic clamp tests (from 225 to 300 minutes) in the per protocol population.</p></caption><media xlink:href="DOM-19-442-s008.pptx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="dom12817-supitem-0007"><caption><p>
<bold>Figure S7</bold>. Glucose infusion rate (<styled-content style="fixed-case">GIR</styled-content>) and <styled-content style="fixed-case">GIR</styled-content> area&#x02010;under&#x02010;the curve (<styled-content style="fixed-case">GIR&#x02010;AUC</styled-content>) after discontinuation of insulin infusion in the per protocol population.</p></caption><media xlink:href="DOM-19-442-s007.pptx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="dom12817-supitem-0008"><caption><p>
<bold>Table S1</bold>. Response to meals in the per protocol population.</p></caption><media xlink:href="DOM-19-442-s002.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="dom12817-supitem-0009"><caption><p>
<bold>File S1</bold>. Blood sampling and measurement of hormones.</p></caption><media xlink:href="DOM-19-442-s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="dom12817-sec-0010"><title>ACKNOWLEDGMENTS</title><p id="dom12817-para-0013">The authors are grateful to Toshinari Takamura of Kanazawa University for the protocol for the hyperinsulinaemic clamp test. The authors thank Nobuya Inagaki of Kyoto University, Yuichiro Yamada of Akita University and Kazuhiro Tsumura of Kawasaki City Municipal Hospital for serving as the safety committee for the current clinical trial. The authors also thank Yoko Shigefuku of Kansai Electric Power Medical Research Institute and Michiko Yamane of Kansai Electric Power Hospital for secretarial assistance. The writing of this article was supported by A2 Healthcare Corp.</p><sec id="dom12817-sec-0011"><title>Conflict of interest</title><p id="dom12817-para-0014">D. Y. received consulting and/or speaker fees from Eli Lilly Japan K.K., MSD K.K., Sanofi K.K., Novo Nordisk Pharma Ltd., Nippon Boehringer Ingelheim Co., Ltd., Takeda Pharmaceutical Company Limited and Taisho Toyama Pharmaceutical Co. Ltd. D. Y. also received clinical commissioned/joint research grants from Nippon Boehringer Ingelheim Co., Ltd., Eli Lilly and Company, Taisho Toyama Pharmaceutical Co. Ltd. and MSD K.K. S. S. received consulting and/or speaker fees from Sumitomo Dainippon Pharma Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc. S. S. also received clinical commissioned/joint research grants from Sumitomo Dainippon Pharma Co. Ltd., MSD, K.K., Novo Nordisk Pharma Ltd., Takeda Pharmaceutical Company Limited, Eli Lilly Japan, K.K., Sanofi, K.K., Mitsubishi Tanabe Pharma Corporation, Astellas Pharma Inc., Daiichi Sankyo Company and Limited, Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K. and Taisho Pharmaceutical Co., Ltd. T. K. received consulting and/or speaker fees from Astellas Pharma Inc., Nippon Boehringer Ingelheim Co., Ltd., Sanofi K.K., Novo Nordisk Pharma Inc., MSD, K.K., Takeda Pharmaceutical Company Limited, Kowa Company, Ltd., Astellas Pharma Inc., Tanabe Mitsubishi Pharma Corporation, Kaken Pharmaceutical Co., Ltd., AstraZeneca, Daiichi&#x02010;Sankyo Co., Ltd. and Kyowa Hakko Kirin Co., Ltd. T. K. also received clinical commissioned/joint research grants from Nippon Boehringer Ingelheim Co., Ltd., Novo Nordisk Pharma Inc., MSD K.K., Takeda Parmaceutical Company Limited, Ono Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Teijin limited, and Sanofi K.K. B. A. has consulted for Novartis, Glaxo&#x02010;SmithKline, Merck, Sanofi, Novo Nordisk, Boehringer Ingelheim and Takeda and has received lecture fees from Novartis A/S, Merck, Novo Nordisk, Sanofi, Bristol Myers Squibb, AstraZeneca and GlaxoSmithKline. Y. S. received consulting and/or speaker fees from Eli Lilly Japan K.K., Sanofi K.K., Novo Nordisk Pharma Inc., Glaxo&#x02010;Smith&#x02010;Kline, Taisho Pharmaceutical Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Astellas Pharma Inc., BD, Nippon Boehringer Ingelheim Co., Ltd., Johnson &#x00026; Johnson and Takeda Pharmaceutical Company Limited. Y. S. also received clinical commissioned/joint research grants from Taisho Toyama Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Eli Lilly and MSD, K.K. T. E., S. I., M. S., K. M., Y. S. and H. K. report no conflict of interest relevant to this study.</p></sec><sec id="dom12817-sec-0012"><title>Author contributions</title><p id="dom12817-para-0015">D. Y. and Y. S. contributed to the conception and design of the research and writing of the manuscript. T. E., S. I. and M. S. contributed to the design of the research, collection of data, and critical revision of the manuscript for important intellectual content. H. K., K. T., Y. S., S. S. and B. A. contributed to the analysis and interpretation of data and critical revision of the manuscript for important intellectual content. K. M. contributed to the design of the research, statistical analysis and critical revision of the manuscript for important intellectual content. All authors approved the version to be published. D. Y. and Y. S. are the guarantors of this work.</p></sec></ack><ref-list content-type="cited-references" id="dom12817-bibl-0001"><title>REFERENCES</title><ref id="dom12817-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="dom12817-cit-0001">
<string-name>
<surname>Deacon</surname>
<given-names>CF</given-names>
</string-name>, <string-name>
<surname>Holst</surname>
<given-names>JJ</given-names>
</string-name>. <article-title>Dipeptidyl peptidase&#x02010;4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety</article-title>. <source>Expert Opin Pharmacother</source>. <year>2013</year>;<volume>14</volume>:<fpage>2047</fpage>&#x02010;<lpage>2058</lpage>.<pub-id pub-id-type="pmid">23919507</pub-id></mixed-citation></ref><ref id="dom12817-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="dom12817-cit-0002">
<string-name>
<surname>Seino</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Kuwata</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Yabe</surname>
<given-names>D</given-names>
</string-name>. <article-title>Incretin&#x02010;based drugs for type 2 diabetes: focus on East Asian perspectives</article-title>. <source>J Diabetes Invest</source>. <year>2016</year>;<volume>7</volume>:<fpage>102</fpage>&#x02010;<lpage>109</lpage>.</mixed-citation></ref><ref id="dom12817-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="dom12817-cit-0003">
<string-name>
<surname>Seino</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Fukushima</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Yabe</surname>
<given-names>D</given-names>
</string-name>. <article-title>GIP and GLP&#x02010;1, the two incretin hormones: silimarities and differences</article-title>. <source>J Diabetes Invest</source>. <year>2010</year>;<volume>1</volume>:<fpage>9</fpage>&#x02010;<lpage>23</lpage>.</mixed-citation></ref><ref id="dom12817-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="dom12817-cit-0004">
<string-name>
<surname>Drucker</surname>
<given-names>DJ</given-names>
</string-name>. <article-title>Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls</article-title>. <source>Diabetes</source>. <year>2013</year>;<volume>62</volume>:<fpage>3316</fpage>&#x02010;<lpage>3323</lpage>.<pub-id pub-id-type="pmid">23818527</pub-id></mixed-citation></ref><ref id="dom12817-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="dom12817-cit-0005">
<string-name>
<surname>Nauck</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Heimesaat</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Behle</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Effects of glucagon&#x02010;like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2002</year>;<volume>87</volume>:<fpage>1239</fpage>&#x02010;<lpage>1246</lpage>.<pub-id pub-id-type="pmid">11889194</pub-id></mixed-citation></ref><ref id="dom12817-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="dom12817-cit-0006">
<string-name>
<surname>Nauck</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Heimesaat</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Orskov</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Holst</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Ebert</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Creutzfeldt</surname>
<given-names>W</given-names>
</string-name>. <article-title>Preserved incretin activity of glucagon&#x02010;like peptide 1 [7&#x02013;36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type&#x02010;2 diabetes mellitus</article-title>. <source>J Clin Invest</source>. <year>1993</year>;<volume>91</volume>:<fpage>301</fpage>&#x02010;<lpage>307</lpage>.<pub-id pub-id-type="pmid">8423228</pub-id></mixed-citation></ref><ref id="dom12817-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="dom12817-cit-0007">
<string-name>
<surname>Christensen</surname>
<given-names>MB</given-names>
</string-name>, <string-name>
<surname>Calanna</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Holst</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Vilsboll</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Knop</surname>
<given-names>FK</given-names>
</string-name>. <article-title>Glucose&#x02010;dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2014</year>;<volume>99</volume>:<fpage>E418</fpage>&#x02010;<lpage>E426</lpage>.<pub-id pub-id-type="pmid">24423311</pub-id></mixed-citation></ref><ref id="dom12817-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="dom12817-cit-0008">
<string-name>
<surname>Taminato</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Seino</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Goto</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Inoue</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Kadowaki</surname>
<given-names>S</given-names>
</string-name>. <article-title>Synthetic gastric inhibitory polypeptide. Stimulatory effect on insulin and glucagon secretion in the rat</article-title>. <source>Diabetes</source>. <year>1977</year>;<volume>26</volume>:<fpage>480</fpage>&#x02010;<lpage>484</lpage>.<pub-id pub-id-type="pmid">323091</pub-id></mixed-citation></ref><ref id="dom12817-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="dom12817-cit-0009">
<string-name>
<surname>Christensen</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Vedtofte</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Holst</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Vilsboll</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Knop</surname>
<given-names>FK</given-names>
</string-name>. <article-title>Glucose&#x02010;dependent insulinotropic polypeptide: a bifunctional glucose&#x02010;dependent regulator of glucagon and insulin secretion in humans</article-title>. <source>Diabetes</source>. <year>2011</year>;<volume>60</volume>:<fpage>3103</fpage>&#x02010;<lpage>3109</lpage>.<pub-id pub-id-type="pmid">21984584</pub-id></mixed-citation></ref><ref id="dom12817-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="dom12817-cit-0010">
<string-name>
<surname>Malmgren</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ahren</surname>
<given-names>B</given-names>
</string-name>. <article-title>DPP&#x02010;4 inhibition contributes to the prevention of hypoglycaemia through a GIP&#x02010;glucagon counterregulatory axis in mice</article-title>. <source>Diabetologia</source>. <year>2015</year>;<volume>58</volume>:<fpage>1091</fpage>&#x02010;<lpage>1099</lpage>.<pub-id pub-id-type="pmid">25660260</pub-id></mixed-citation></ref><ref id="dom12817-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="dom12817-cit-0011">
<string-name>
<surname>Ahren</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Schweizer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Dejager</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Vildagliptin enhances islet responsiveness to both hyper&#x02010; and hypoglycemia in patients with type 2 diabetes</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2009</year>;<volume>94</volume>:<fpage>1236</fpage>&#x02010;<lpage>1243</lpage>.<pub-id pub-id-type="pmid">19174497</pub-id></mixed-citation></ref><ref id="dom12817-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="dom12817-cit-0012">
<string-name>
<surname>Hompesch</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Jones&#x02010;Leone</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Carr</surname>
<given-names>MC</given-names>
</string-name>, et al. <article-title>Albiglutide does not impair the counter&#x02010;regulatory hormone response to hypoglycaemia: a randomized, double&#x02010;blind, placebo&#x02010;controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus</article-title>. <source>Diabetes Obes Metab</source>. <year>2015</year>;<volume>17</volume>:<fpage>82</fpage>&#x02010;<lpage>90</lpage>.<pub-id pub-id-type="pmid">25263215</pub-id></mixed-citation></ref><ref id="dom12817-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="dom12817-cit-0013">
<string-name>
<surname>Farngren</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Persson</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ahren</surname>
<given-names>B</given-names>
</string-name>. <article-title>Effect of the GLP&#x02010;1 receptor agonist lixisenatide on counterregulatory responses to hypoglycemia in subjects with insulin&#x02010;treated type 2 diabetes</article-title>. <source>Diabetes Care</source>. <year>2016</year>;<volume>39</volume>:<fpage>242</fpage>&#x02010;<lpage>249</lpage>.<pub-id pub-id-type="pmid">26537183</pub-id></mixed-citation></ref><ref id="dom12817-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="dom12817-cit-0014">
<string-name>
<surname>Farngren</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Persson</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Schweizer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Foley</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Ahren</surname>
<given-names>B</given-names>
</string-name>. <article-title>Glucagon dynamics during hypoglycaemia and food&#x02010;re&#x02010;challenge following treatment with vildagliptin in insulin&#x02010;treated patients with type 2 diabetes</article-title>. <source>Diabetes Obes Metab</source>. <year>2014</year>;<volume>16</volume>:<fpage>812</fpage>&#x02010;<lpage>818</lpage>.<pub-id pub-id-type="pmid">24612221</pub-id></mixed-citation></ref><ref id="dom12817-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="dom12817-cit-0015">
<string-name>
<surname>Yabe</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Seino</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Fukushima</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Seino</surname>
<given-names>S</given-names>
</string-name>. <article-title>Beta cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians</article-title>. <source>Curr Diab Rep</source>. <year>2015</year>;<volume>15</volume>:<fpage>602</fpage>.<pub-id pub-id-type="pmid">25944304</pub-id></mixed-citation></ref><ref id="dom12817-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="dom12817-cit-0016">
<string-name>
<surname>Kim</surname>
<given-names>YG</given-names>
</string-name>, <string-name>
<surname>Hahn</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Oh</surname>
<given-names>TJ</given-names>
</string-name>, <string-name>
<surname>Kwak</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>KS</given-names>
</string-name>, <string-name>
<surname>Cho</surname>
<given-names>YM</given-names>
</string-name>. <article-title>Differences in the glucose&#x02010;lowering efficacy of dipeptidyl peptidase&#x02010;4 inhibitors between Asians and Non&#x02010;Asians: a systematic review and meta&#x02010;analysis</article-title>. <source>Diabetologia</source>. <year>2013</year>;<volume>56</volume>:<fpage>696</fpage>&#x02010;<lpage>708</lpage>.<pub-id pub-id-type="pmid">23344728</pub-id></mixed-citation></ref><ref id="dom12817-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="dom12817-cit-0017">
<string-name>
<surname>Kim</surname>
<given-names>YG</given-names>
</string-name>, <string-name>
<surname>Hahn</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Oh</surname>
<given-names>TJ</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>KS</given-names>
</string-name>, <string-name>
<surname>Cho</surname>
<given-names>YM</given-names>
</string-name>. <article-title>Differences in the HbA1c&#x02010;lowering efficacy of glucagon&#x02010;like peptide&#x02010;1 analogues between Asians and non&#x02010;Asians: a systematic review and meta&#x02010;analysis</article-title>. <source>Diabetes Obes Metab</source>. <year>2014</year>;<volume>16</volume>:<fpage>900</fpage>&#x02010;<lpage>909</lpage>.<pub-id pub-id-type="pmid">24655583</pub-id></mixed-citation></ref><ref id="dom12817-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="dom12817-cit-0018">
<string-name>
<surname>Aaboe</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Akram</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Deacon</surname>
<given-names>CF</given-names>
</string-name>, <string-name>
<surname>Holst</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Madsbad</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Krarup</surname>
<given-names>T</given-names>
</string-name>. <article-title>Restoration of the insulinotropic effect of glucose&#x02010;dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase&#x02010;4 inhibitors</article-title>. <source>Diabetes Obes Metab</source>. <year>2015</year>;<volume>7</volume>:<fpage>74</fpage>&#x02010;<lpage>81</lpage>.</mixed-citation></ref><ref id="dom12817-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="dom12817-cit-0019">
<string-name>
<surname>Farngren</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Persson</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Schweizer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Foley</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Ahren</surname>
<given-names>B</given-names>
</string-name>. <article-title>Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2012</year>;<volume>97</volume>:<fpage>3799</fpage>&#x02010;<lpage>3806</lpage>.<pub-id pub-id-type="pmid">22855332</pub-id></mixed-citation></ref><ref id="dom12817-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="dom12817-cit-0020">
<string-name>
<surname>Pieber</surname>
<given-names>TR</given-names>
</string-name>, <string-name>
<surname>Deller</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Korsatko</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Counter&#x02010;regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo&#x02010;controlled, double&#x02010;blind, crossover trial</article-title>. <source>Diabetes Obes Metab</source>. <year>2015</year>;<volume>17</volume>:<fpage>742</fpage>&#x02010;<lpage>750</lpage>.<pub-id pub-id-type="pmid">25855340</pub-id></mixed-citation></ref></ref-list></back></article>